Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Pembrolizumab |
Indication/Tumor Type | malignant pleural mesothelioma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | malignant pleural mesothelioma | predicted - sensitive | Pembrolizumab | Phase I | Actionable | In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in an objective response rate of 20% (5/25) and a stable disease rate of 52% (13/25) in previously treated patients with malignant pleural mesothelioma that had CD274 (PD-L1) expression in 1% or more of tumor cells by IHC, with a median duration of response of 12 months (PMID: 28291584; NCT02054806). | 28291584 |
PubMed Id | Reference Title | Details |
---|---|---|
(28291584) | Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. | Full reference... |